通用幹細胞股份有限公司

Taichung, Taiwan Founded: 2022 • Age: 4 yrs
Established in 2022 in Taichung, Taiwan, as a limited company.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About 通用幹細胞股份有限公司

通用幹細胞股份有限公司 is a company based in Taichung (Taiwan) founded in 2022. 通用幹細胞股份有限公司 offers products and services including Cell Culture Medium and Closed Cell Culture System.

  • Headquarter Taichung, Taiwan
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Duogenic Stemcells Corporation
Operational Areas
Healthcare → Healthcare Education, Research & Associations
Key Metrics
  • Annual Revenue
    $12.05 M
    -11.82
    as on Dec 31, 2024
  • Net Profit
    -$61.58 M
    -36.13
    as on Dec 31, 2024
  • EBITDA
    -$53.73 M
    -41.86
    as on Dec 31, 2024
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of 通用幹細胞股份有限公司

通用幹細胞股份有限公司 is a publicly listed company on the TPEX with ticker symbol 7607 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TPEX · Ticker: 7607 · Sector: Health technology · Taiwan

Products & Services of 通用幹細胞股份有限公司

通用幹細胞股份有限公司 offers a comprehensive portfolio of products and services, including Cell Culture Medium and Closed Cell Culture System.

Primary

Cell culture media are provided by DuoGenic StemCells for cultivating human cells in 2D and 3D environments, with these media being certified and suitable for research and clinical applications

A closed cell culture system is offered by DuoGenic StemCells using bags for cell growth, which is intended to lower production costs and support the expansion of cell therapy

Funding Insights of 通用幹細胞股份有限公司

Investments & Acquisitions by 通用幹細胞股份有限公司

Investments

Financial Statements - 通用幹細胞股份有限公司

通用幹細胞股份有限公司 Comparisons

+
Add Comparison
Available on Premium

Competitors of 通用幹細胞股份有限公司

Latest news on 通用幹細胞股份有限公司

Frequently Asked Questions about 通用幹細胞股份有限公司

通用幹細胞股份有限公司 was founded in 2022.

通用幹細胞股份有限公司 is headquartered in Taichung, Taiwan.

通用麵細胞股份有限公司 was founded in 2022 and is based in Taichung, Taiwan. Operations are managed from this location, with an online presence maintained through the domain dgsc.com.tw. The company functions as a limited liability entity, though specific sectors or services are not detailed in available records. Focus is placed on standard corporate activities in the Taiwanese market.

通用幹細胞股份有限公司 offers Cell Culture Medium and Closed Cell Culture System.

Yes, 通用幹細胞股份有限公司 is publicly traded on TPEX under the ticker symbol 7607.

The ticker symbol of 通用幹細胞股份有限公司 is 7607 on TPEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available